Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hatch Closing Act: OTC Monograph Reform Legislation?

Executive Summary

The Utah Republican has been instrumental during his more than 40 years in office in passing legislation central to the growth of the OTC drug and dietary supplement industries. But the expansion of the OTC market is stifled by FDA's monograph system for making more ingredients available, a process agency officials say no longer works.

You may also be interested in...



Capitol Hill Calm On Regulatory Front Before Mid-Term Elections Storm

Federal agencies have “put brakes on new regulations” during the Trump administration and made efforts toward deregulation across the board, bringing about a “good and friendly environment for most businesses and industries,” says lobbyist Pete Evich. “We need to be careful about complacency that has a tendency to creep back in at a time like this when direct attacks and threats are down,” he said in a recent webinar.

SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill

The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

Exclusivity Provision Surfaces In OTC Monograph Bill

The House Health subcommittee asks whether allowing manufacturers' periods of US market exclusivity for some approved OTC monograph proposals is needed, or would be fair to consumers.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS122261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel